^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kadcyla (ado-trastuzumab emtansine)

    i
    Company:
    AbbVie, Roche
    Drug class:
    Microtubule inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer (NCT02226276)
    Phase N/A
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/07/2015
    Primary completion :
    12/07/2021
    Completion :
    10/30/2025
    HER-2
    |
    HER-2 positive • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine)
    Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas (NCT04620187)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    12/24/2020
    Primary completion :
    02/01/2026
    Completion :
    02/01/2027
    HER-2
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    cisplatin • carboplatin • Kadcyla (ado-trastuzumab emtansine)
    Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (NCT04589845)
    Phase 2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/18/2021
    Primary completion :
    09/25/2032
    Completion :
    09/25/2032
    BRAF
    |
    Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)
    A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer) (NCT05415215)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/05/2022
    Primary completion :
    11/20/2024
    Completion :
    12/31/2025
    HER-2
    |
    HER-2 amplification • EGFR positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (NCT06348134)
    Phase 2
    University of Chicago
    Not yet recruiting
    Last update posted :
    02/05/2025
    Initiation :
    01/01/2026
    Primary completion :
    07/01/2034
    Completion :
    07/01/2036
    HER-2
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
    A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe) (NCT05081609)
    Phase 1/2
    Ascendis Pharma Oncology Division A/S
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    01/11/2022
    Primary completion :
    08/01/2027
    Completion :
    08/01/2029
    IL2
    |
    Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)
    T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) (NCT01853748)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    05/01/2013
    Primary completion :
    08/26/2019
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • paclitaxel • Kadcyla (ado-trastuzumab emtansine)
    Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease (KAN-HER2 MRD) (NCT05388149)
    Phase 2
    University Health Network, Toronto
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    12/06/2022
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    HER-2
    |
    HER-2 positive
    |
    Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)
    A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 (NCT03032107)
    Phase 1
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    01/27/2025
    Initiation :
    02/17/2017
    Primary completion :
    10/29/2020
    Completion :
    12/05/2024
    HER-2 • PGR
    |
    Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine)
    Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib (BRIDGET) (NCT05323955)
    Phase 2
    Carey Anders, M.D.
    Recruiting
    Last update posted :
    12/11/2024
    Initiation :
    03/23/2023
    Primary completion :
    10/01/2026
    Completion :
    10/01/2027
    HER-2
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)
    A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) (NCT03726879)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    11/05/2024
    Initiation :
    01/11/2019
    Primary completion :
    02/05/2021
    Completion :
    08/24/2023
    HER-2 • PD-L1 • ER • PGR
    |
    PD-L1 expression • HER-2 positive • ER negative
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous
    DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] (NCT03523585)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    11/05/2024
    Initiation :
    08/01/2018
    Primary completion :
    06/30/2022
    Completion :
    07/31/2025
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    lapatinib • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) (NCT04622319)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    10/09/2024
    Initiation :
    12/04/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2030
    HER-2 • ER • PGR
    |
    HER-2 positive • HR positive • HER-2 expression • ER negative
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer (NCT02390427)
    Phase 1
    Otto Metzger, MD
    Completed
    Last update posted :
    10/02/2024
    Initiation :
    04/20/2015
    Primary completion :
    12/01/2022
    Completion :
    07/01/2024
    HER-2
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • taselisib (GDC-0032)
    A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) ( DESTINY-Breast01) (NCT03248492)
    Phase 2
    Daiichi Sankyo
    Completed
    Last update posted :
    09/24/2024
    Initiation :
    08/25/2017
    Primary completion :
    03/21/2019
    Completion :
    05/06/2024
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    HER2 Molecular Imaging with 89Zr-trastuzumab PET/CT As a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients with Advanced HER2-positive Breast Cancer (ZEPHIR-02) (NCT06595563)
    Phase 2
    Jules Bordet Institute
    Not yet recruiting
    Last update posted :
    09/13/2024
    Initiation :
    01/01/2025
    Primary completion :
    03/01/2028
    Completion :
    09/01/2029
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Kadcyla (ado-trastuzumab emtansine)
    T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (NCT02326974)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    08/07/2024
    Initiation :
    01/01/2015
    Primary completion :
    06/01/2018
    Completion :
    01/01/2028
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine)
    A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET) (NCT04931342)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    10/07/2021
    Primary completion :
    05/30/2028
    Completion :
    12/31/2028
    ER
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (GDC-9545)
    DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] (NCT03529110)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    08/09/2018
    Primary completion :
    05/21/2021
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    ATEMPT 2.0: Adjuvant T-DM1 vs TH (NCT04893109)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/16/2021
    Primary completion :
    05/01/2025
    Completion :
    05/01/2028
    HER-2
    |
    HER-2 positive • HER-2 negative
    |
    Herceptin (trastuzumab) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02) (NCT03975647)
    Phase 3
    Seagen Inc.
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    10/02/2019
    Primary completion :
    06/29/2023
    Completion :
    10/31/2027
    HER-2
    |
    Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)
    ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (NCT05650879)
    Phase 1
    Enliven Therapeutics
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    03/20/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    BRAF • ALK • ROS1
    |
    HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ELVN-002
    T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial (A011801) (NCT04457596)
    Phase 3
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    01/06/2021
    Primary completion :
    01/01/2028
    Completion :
    05/01/2035
    ER • PGR
    |
    HER-2 positive • ER positive • HR positive • HR negative • ER negative
    |
    cisplatin • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)
    A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer (NCT05945927)
    Phase N/A
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    09/13/2023
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    HER-2
    |
    HER-2 positive
    |
    Kadcyla (ado-trastuzumab emtansine)
    HKI-272 for HER2-Positive Breast Cancer and Brain Metastases (NCT01494662)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    05/22/2024
    Initiation :
    02/01/2012
    Primary completion :
    02/01/2023
    Completion :
    12/01/2024
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine) • capecitabine
    A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania) (NCT04873362)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    05/15/2024
    Initiation :
    05/04/2021
    Primary completion :
    06/25/2026
    Completion :
    06/29/2035
    HER-2 • PD-L1
    |
    EGFR positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Kadcyla (ado-trastuzumab emtansine)
    Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers (NCT02675829)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/08/2024
    Initiation :
    02/01/2016
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    HER-2 • MUC16
    |
    HER-2 amplification • HER-2 L755S • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 A775 • HER-2 YVMA
    |
    Kadcyla (ado-trastuzumab emtansine)
    Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) (NCT04439110)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/08/2024
    Initiation :
    08/12/2015
    Primary completion :
    03/09/2019
    Completion :
    03/07/2025
    HER-2
    |
    HER-2 amplification
    |
    Kadcyla (ado-trastuzumab emtansine)
    A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) (NCT01772472)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    05/02/2024
    Initiation :
    04/03/2013
    Primary completion :
    07/25/2018
    Completion :
    05/15/2024
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine)
    CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (NCT04266249)
    Phase 2
    ECOG-ACRIN Cancer Research Group
    Recruiting
    Last update posted :
    04/18/2024
    Initiation :
    03/13/2020
    Primary completion :
    10/31/2026
    Completion :
    12/31/2038
    ER • PGR
    |
    HER-2 positive • HER-2 negative
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • albumin-bound paclitaxel • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar)
    Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction (SCHOLAR-2) (NCT04680442)
    Phase 2
    Population Health Research Institute
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    07/01/2021
    Primary completion :
    01/01/2025
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)
    Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2) (NCT04733118)
    Phase 2
    MedSIR
    Active, not recruiting
    Last update posted :
    03/13/2024
    Initiation :
    08/05/2021
    Primary completion :
    09/01/2025
    Completion :
    03/01/2028
    HER-2 • ER • PGR
    |
    tamoxifen • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) (NCT01120184)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/04/2024
    Initiation :
    07/31/2010
    Primary completion :
    09/30/2014
    Completion :
    09/16/2016
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine)
    A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) (NCT05673928)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/29/2024
    Initiation :
    05/16/2023
    Primary completion :
    03/01/2027
    Completion :
    03/01/2029
    HER-2
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification
    |
    Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)
    Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer (NRG-HN010) (NCT05408845)
    Phase 2
    NRG Oncology
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    09/30/2022
    Primary completion :
    07/31/2028
    Completion :
    07/31/2028
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • docetaxel • Kadcyla (ado-trastuzumab emtansine) • Trazimera (trastuzumab-qyyp)
    SMMART Adaptive Clinical Treatment (ACT) Trial (NCT05238831)
    Phase 1
    OHSU Knight Cancer Institute
    Withdrawn
    Last update posted :
    01/23/2024
    Initiation :
    01/30/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2026
    HER-2 • BRCA1 • BRCA2
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)
    A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients (NCT05889988)
    Phase N/A
    Mayo Clinic
    Recruiting
    Last update posted :
    01/08/2024
    Initiation :
    06/12/2023
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive
    |
    Kadcyla (ado-trastuzumab emtansine)
    TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery (ACCRU-BR-1701) (NCT04197687)
    Phase 2
    Academic and Community Cancer Research United
    Recruiting
    Last update posted :
    12/18/2023
    Initiation :
    02/20/2020
    Primary completion :
    01/15/2025
    Completion :
    01/15/2025
    HER-2 • ER • PGR
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • HER-2/neu peptide vaccine • Leukine (sargramostim) • TPIV100